References
Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413–6.
Kremer JM, Cohen S, Wilkinson B, et al: Safety and efficacy after 24 weeks dosing of oral JAK inhibitor CP-690,550 in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60(S719):1925 (abstract).
Tanaka Y, Suzuki M, Nakamura H, et al: The oral JAK inhibitor CP-690,550 in combination with methotrexate is efficacious, safe and well tolerated in Japanese patients with active rheumatoid arthritis with an inadequate response to MTX alone. Abstract presented at the European League Against Rheumatism, Copenhagen, Denmark, June 10–13, 2009.
Kanik K, Fleschmann RM, Cutolo M, et al: Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate reponse to DMARDs. Ann Rheum Dis 2009, 68:123 OP-0159 (abstract).
Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patel, A.M., Lupash, D., Chew, D. et al. JAK Inhibition in Rheumatoid Arthritis. Curr Rheumatol Rep 13, 379–380 (2011). https://doi.org/10.1007/s11926-011-0196-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-011-0196-4